Sobi Reports Impressive Q2 2025 Financial Performance
Swedish Orphan Biovitrum AB (publ) (SOBI) recently unveiled its financial results for the second quarter of 2025, reflecting notable progress in revenue generation and operational efficiency.
Key Financial Highlights
The company reported a robust increase in total revenue, which surged by 13% year-over-year. When adjusted for constant exchange rates, the growth was even more pronounced at 22%, culminating in revenue of SEK 6,175 million.
Breaking down the figures, the haematology segment showcased substantial performance with a revenue rise of 27% at constant exchange rates, bringing in SEK 4,570 million. This increase was predominantly due to the introduction of Altuvoct, which generated SEK 627 million, alongside strong sales of Doptelet and Aspaveli/Empaveli, contributing SEK 1,220 million and SEK 304 million respectively.
Sales in Immunology and Strategic Portfolio
The immunology division also posted an impressive revenue growth of 11%, amounting to SEK 1,288 million, fueled by notable sales figures for Gamifant and Kineret. The strategic portfolio, which includes several significant products, showcased exceptional growth, increasing by 65% to reach SEK 3,384 million.
Operational Profitability and Earnings
The adjusted EBITA margin improved to 34%, up from 28% in the prior year, reflecting the company's efforts to enhance operational efficiency despite restructuring costs associated with organizational changes. EBITA for the quarter was reported at SEK 1,863 million, with a margin increase as well.
Both the before and after dilution earnings per share witnessed significant improvement, with figures of SEK 1.85 and SEK 1.83 respectively. Adjusted figures also showed a rise, demonstrating Sobi's strong financial health.
Company Outlook and Future Expectations
Looking ahead, Sobi maintains its outlook for 2025, expecting a high single-digit revenue growth at constant exchange rates. The company projects that its adjusted EBITA margin will stabilize in the mid-30s percentage range, indicating a commitment to sustained financial performance.
Conclusion: Sobi's Path Forward
The impressive metrics from Sobi's Q2 2025 report reveal a company on a solid growth trajectory. With enhanced revenue from both haematology and immunology sectors and a strong strategic portfolio, Sobi is well-positioned for continued success in the biopharmaceutical landscape.
Frequently Asked Questions
What were Sobi's total revenues for Q2 2025?
Sobi reported total revenues of SEK 6,175 million for Q2 2025, reflecting significant growth over the previous year.
How much did the haematology revenue increase?
The haematology revenue increased by 27% at constant exchange rates to SEK 4,570 million, primarily driven by the launch of Altuvoct.
What earnings did Sobi report for Q2 2025?
Sobi reported earnings per share of SEK 1.85 before dilution and SEK 1.83 after dilution for Q2 2025.
What is Sobi's outlook for 2025?
Sobi anticipates a high single-digit percentage growth in revenue at constant exchange rates and expects a stable EBITA margin in the mid-30s.
How does Sobi's performance in immunology compare to haematology?
While haematology revenues grew by 27%, the immunology segment also showed strong growth, increasing by 11% in Q2 2025, indicating healthy performance across both sectors.
